Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.78 |
| ▸ | THRB | P10828 | 4/20 | 0.75 |
| ▸ | MAPT | P10636 | 6/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 10/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | CASP1 | P29466 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1412303 | 0.91 | MAPT (0.74) | SMN1; SMN2THRBMAPTALDH1A1MEN1 | |
| SCHEMBL1412344 | 0.90 | SMN1; SMN2 (0.80) | SMN1; SMN2THRBMAPTALDH1A1TP53 | |
| SCHEMBL1414910 | 0.84 | SMN1; SMN2 (0.73) | SMN1; SMN2THRBMAPTALDH1A1TP53 | |
| SCHEMBL1412391 | 0.83 | TP53 (0.75) | SMN1; SMN2THRBMAPTTP53LMNA | |
| SCHEMBL1412295 | 0.83 | THRB (0.84) | SMN1; SMN2THRBMAPTTP53LMNA | |
| SCHEMBL2017456 | 0.81 | MAPT (0.75) | SMN1; SMN2THRBMAPTALDH1A1MEN1 | |
| SCHEMBL1412266 | 0.81 | KAT8 (0.86) | SMN1; SMN2THRBMAPTTP53LMNA | |
| SCHEMBL1412328 | 0.81 | SMN1; SMN2 (0.71) | SMN1; SMN2THRBMAPTTP53LMNA | |
| SCHEMBL1412236 | 0.81 | MAPT (0.87) | SMN1; SMN2THRBMAPTALDH1A1APOBEC3A | |
| SCHEMBL1412265 | 0.80 | MAPT (0.71) | SMN1; SMN2THRBMAPTALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150202195-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2015-07-23 | — | — | US | claimed |
| US-9029376-B2 | Small molecule inhibitors for the treatment or prevention of dengue virus infection | SIGA TECHNOLOGIES, INC. (US) | 2015-05-12 | — | — | US | claimed |
| US-20110158940-A1 | SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-06-30 | — | — | US | claimed |
| EP-2293671-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | Siga Technologies, Inc. (US) | 2011-03-16 | — | — | EP | claimed |
| WO-2009149054-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2009-12-10 | — | — | WO | claimed |
| US-20150202195-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150202195-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150202195-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-9029376-B2 | Small molecule inhibitors for the treatment or prevention of dengue virus infection | SIGA TECHNOLOGIES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029376-B2 | Small molecule inhibitors for the treatment or prevention of dengue virus infection | SIGA TECHNOLOGIES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029376-B2 | Small molecule inhibitors for the treatment or prevention of dengue virus infection | SIGA TECHNOLOGIES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20110158940-A1 | SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110158940-A1 | SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110158940-A1 | SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-06-30 | — | — | US | disclosed |
| EP-2293671-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | Siga Technologies, Inc. (US) | 2011-03-16 | — | — | EP | disclosed |
| WO-2009149054-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202195-A1 | SMALL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | SNRPE, EIF2AK2, HAVCR2 | SMN1; SMN2 1051/4885THRB 2924/4885MAPT 219/4885 |
| US-20110158940-A1 | SAMLL MOLECULE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DENGUE VIRUS INFECTION | HAVCR2, HNRNPLL, SAMSN1 | SMN1; SMN2 1972/4885THRB 2882/4885MAPT 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.